GGGuo-Li Gu

Guo-Li Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guo-Li Gu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Peng-Fei Yu

    China Med Univ, Air Force Med Ctr, Dept Gen Surg, Air Force Clin Coll, 30 Fucheng Rd, Beijing 100142, Peoples R China

    8 shared publications
  • Zhi Zhang

    Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, Hefei 230002, Anhui, Peoples R China

    7 shared publications
  • Hai-Rui Yang

    China Med Univ, Air Force Med Ctr, Dept Gen Surg, Chinese Peoples Liberat Army,Clin Air Force Clin C, Beijing 100142, Peoples R China

    6 shared publications
  • Zhi-Wei Dong

    Department of General Surgery, Air Force Medical Center, Chinese PLA, Beijing 100142, China

    6 shared publications
  • Jing Liu

    4 shared publications
  • Li-Xin Jiang

    Department of General Surgery, Air Force Clinical College, China Medical University, Beijing 100142, China

    3 shared publications

Latest Publications

  • Open Access

    Thyroid cancer in Chinese military flight personnel: Characteristics and management advances

    by Yan Wang, Jing Liu, Chun-Xia Zhang, Guo-Li Gu

    Military flight personnel face a higher risk of developing thyroid cancer than the general population due to prolonged exposure to unique occupational hazards, including high-altitude hypoxia, ionizing radiation, extreme physiological and psychological stress, and irregular diets and work schedules. Thyroid cancer is also the most common malignant tumor among military flight personnel. Military flight personnel diagnosed with thyroid cancer or experiencing complications during treatment will be grounded, which will severely impact military flight combat effectiveness. To better understand characteristics of this disease among military flight personnel, we conducted a literature review of relevant domestic and international studies. This mini-review summarizes recent research progress on the epidemiology, risk factors, clinical features, diagnosis, prevention, and treatment strategies for thyroid cancer in this cohort. The ultimate aim is to inform targeted preventive and therapeutic measures, establish a multidisciplinary system for early screening, standardized treatment, and aeromedical assessment, thereby safeguarding personnel health and ensuring flight safety.

  • Open Access

    Clinicopathological characteristics and surgical value of primary gastrointestinal lymphoma

    by Cong-Xian Yang, Lin-Xiang Xu, Jing Liu, Hui-Lian Qiao, Zhi-Wei Dong, Dan Jiang, Guo-Li Gu

    BACKGROUND Primary gastrointestinal lymphoma (PGIL) is a relatively uncommon clinical entity, exhibiting distinctive features including occult primary sites, nonspecific clinical presentations, and considerable diagnostic and therapeutic difficulties. Consequently, comprehensive clinical investigations into its clinicopathological characteristics and surgical intervention value are warranted to enhance diagnostic and therapeutic proficiency. AIM To investigate the clinicopathological characteristics and surgical significance of PGIL from a surgical perspective, providing a theoretical basis for optimizing diagnostic and therapeutic strategies. METHODS This study included 50 cases of PGIL treated by the General Surgery Department of the Chinese PLA Air Force Medical Center from June 2001 to March 2025. Data were extracted from the Electronic Medical Record system for retrospective analysis. A retrospective analysis was conducted on their epidemiological, clinical manifestations, imaging, pathological features, and treatment outcomes. Descriptive statistics were applied for data summarization, with continuous variables presented as frequencies and percentages. Correlations between variables were assessed using the Spearman rank correlation coefficient. RESULTS All cases had the gastrointestinal tract as the primary site. Abdominal pain was the most common initial symptom (52.0%), with 80.0% of patients experiencing pain during the course of the disease, and 38.0% experiencing hematochezia/melena or anemia. Computed tomography diagnosis exhibited a high overall sensitivity (94.3%); the endoscopic detection rate was 91.5%. Diffuse large B-cell lymphoma was the most common subtype (52.0%). The improvement rate was higher in the surgery combined with chemotherapy group than in the chemotherapy only group. The incidence of postoperative complications was 26.5%, all occurring in patients with tumors > 5 cm. CONCLUSION Diffuse large B-cell lymphoma is the primary PGIL subtype. Imaging and endoscopic biopsy are diagnostic essentials. Surgery aids in resection, complication management, and pathologic diagnosis. Multidisciplinary, individualized strategies are recommended, necessitating further prospective molecular studies.


  • Retraction
    Open Access

    Retraction note to: Idiopathic abdominal cocoon syndrome with unilateral abdominal cryptorchidism and greater omentum hypoplasia

    by Guo-Li Gu

    In this retraction note, we have decided to retract an article published in World Journal of Gastroenterology due to management regulations and disagreement among the authors.

  • Open Access

    Parabacteroides johnsonii inhibits the onset and progression of colorectal cancer by modulating the gut microbiota

    by Jing Liu, Yong Zhang, Linxiang Xu, Guoli Gu, Zhiwei Dong

    Colorectal cancer (CRC) is the third most prevalent malignant tumor and the second leading cause of cancer-related deaths globally. The genus Parabacteroides is an important component of the gut microbiota. P. distasonis and P. goldsteinii are reported probiotics, and their roles in CRC have been investigated in related studies. However, the association between P. johnsonii and CRC remains unknown. P. johnsonii (10–42) and Lactococcus formosensis (22–2) were isolated from healthy human feces. 29 mice that demonstrated normal feeding and activity were randomly assigned to four groups: normal control (NC group), CRC model (IC group), P. johnsonii (PJ group), and L. formosensis (LO group). Colonic tumor tissues from the IC, PJ, and LO groups and normal colon tissues from the NC group were then collected for HE staining and immunohistochemical staining. Fecal samples from mice during the hyperproliferative and adenoma phases were collected for Metagenomic sequencing and metabolite analysis. P. johnsonii intervention reduced the number and slowed the growth of colonic tumors, improved tumor histological scores, and decreased microenvironmental inflammation levels. P. johnsonii improved the composition of intestinal flora in mice with colon cancer, increased gut microbial species diversity, and maintained gut microbiota stability. Furthermore, P. johnsonii intervention increased the abundance of Bifidobacterium pseudolongum and Lactobacillus, which play a role in ameliorating AOM/DSS-induced gut microbiota dysbiosis. P. johnsonii intervention affected the metabolic pathways, including amino sugar degradation and galactose metabolism, sphingolipid synthesis, amino acid synthesis, and polyphenol synthesis pathways, with the tryptophan metabolism pathway as the primary pathway being affected. Our study profiled the P. johnsonii administration reduces the number of tumors and lower tumor staging in AOM/DSS-induced colon cancer mice by modulating gut microbiota and its metabolites at early stages. The online version contains supplementary material available at 10.1186/s12967-025-06675-0.


  • Open Access

    Clinicopathological analysis of small intestinal metastasis from extra-abdominal/extra-pelvic malignancy

    by Zhi Zhang, Jing Liu, Peng-Fei Yu, Hai-Rui Yang, Jin-Yang Li, Zhi-Wei Dong, Wei Shi, Guo-Li Gu

    BACKGROUND The metastatic tumors in the small intestine secondary to extra-abdominal/extra-pelvic malignancy are extremely rare. However, the small intestine metastases are extremely prone to misdiagnosis and missed diagnosis due to the lack of specific clinical manifestations and examination methods, thus delaying its treatment. Therefore, in order to improve clinical diagnosis and treatment capabilities, it is necessary to summarize its clinical pathological characteristics and prognosis. AIM To summarize the clinicopathological characteristics of patients with small intestinal metastases from extra-abdominal/extra-pelvic malignancy, and to improve the clinical capability of diagnosis and treatment for rare metastatic tumors in the small intestine. METHODS The clinical data of patients with small intestinal metastases from extra-abdominal/extra-pelvic malignancy were retrieved and summarized, who admitted to and treated in the Air Force Medical Center, Chinese People’s Liberation Army. Then descriptive statistics were performed on the general conditions, primary tumors, secondary tumors in the small intestine, diagnosis and treatment processes, and prognosis. RESULTS Totally 11 patients (9 males and 2 females) were enrolled in this study, including 8 cases (72.3%) of primary lung cancer, 1 case (9.1%) of malignant lymphoma of the thyroid, 1 case (9.1%) of cutaneous malignant melanoma, and 1 case (9.1%) of testicular cancer. The median age at the diagnosis of primary tumors was 57.9 years old, the median age at the diagnosis of metastatic tumors in the small intestine was 58.81 years old, and the average duration from initial diagnosis of primary tumors to definite diagnosis of small intestinal metastases was 9 months (0-36 months). Moreover, small intestinal metastases was identified at the diagnosis of primary tumors in 4 cases. The small intestinal metastases were distributed in the jejunum and ileum, with such clinical manifestations as hematochezia (5, 45.4%) and abdominal pain, vomiting and other obstruction (4, 36.4%). In addition, 2 patients had no obvious symptoms at the diagnosis of small intestinal metastases, and 5 patients underwent radical resection of small intestinal malignancies and recovered well after surgery. A total of 3 patients did not receive subsequent treatment due to advanced conditions. CONCLUSION Small intestinal metastases of extra-abdominal/extra-pelvic malignancy is rare with high malignancy and great difficulty in diagnosis and treatment. Clinically, patients with extra-abdominal/extra-pelvic malignancy should be alert to the occurrence of this disease, and their prognosis may be improved through active surgery combined with standard targeted therapy.


  • Open Access

    A recurrence‐predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer

    by Zhaoya Gao, Zhiyi Wan, Pengfei Yu, Yan Shang, Guangsheng Zhu, Huiyuan Jiang, Yawei Chen, Shengzhou Wang, Fuming Lei, Wensheng Huang, et al.

    Background: Although adjuvant chemotherapy (ACT) is widely used to treat patients with Stage II/III colorectal cancer (CRC), administering ACT to specific patients remains a challenge. The decision to ACT requires an accurate assessment of recurrence risk and absolute treatment benefit. However, the traditional TNM staging system does not accurately assess a patient's individual risk of recurrence.Methods: To identify recurrence risk‐related genetic factors for Stage II/III CRC patients after radical surgery, we conducted an analysis of whole‐exome sequencing of 47 patients with Stage II/III CRC who underwent radical surgery at five institutions. Patients were grouped into non‐recurrence group (NR, n = 24, recurrence‐free survival [RFS] > 5 years) and recurrence group (R, n = 23, RFS CUL9, PCDHA12, HECTD3, DCX, SMARCA2, FAM193A, AATK, and SORCS2) mutations and tumor mutation burden/microsatellite instability (TMB/MSI) status was constructed, with 97.87% accuracy in our data and 100% negative predictive value in the TCGA‐COAD/READ cohort. For the TCGA‐COAD/READ cohort, the G8plus‐high group had better RFS (HR = 0.22, p = 0.024); the G8plus‐high tumors had significantly more infiltrated immune cell types, higher tertiary lymphoid structure signature scores, and higher immunological signature scores. The G8plus score was also a predict biomarker for immunotherapeutic in advanced CRC in the PUCH cohort.Conclusions: In conclusion, the G8plus score is a powerful biomarker for predicting the risk of recurrence in patients with stage II/III CRC. It can be used to stratify patients who benefit from ACT and immunotherapy.


  • Open Access

    Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis

    by Yu-Rui Chen, Zu-Xin Xu, Li-Xin Jiang, Zhi-Wei Dong, Peng-Fei Yu, Zhi Zhang, Guo-Li Gu

    BACKGROUND Breast cancer (BC) has become the most common malignancy in women. The incidence and detection rates of BC brain metastasis (BCBM) have increased with the progress of imaging, multidisciplinary treatment techniques and the extension of survival time of BC patients. BM seriously affects the quality of life and sur-vival prognosis of BC patients. Therefore, clinical research on the clinicopathological features and prognostic factors of BCBM is valuable. By analyzing the clinicopathological parameters of BCBM patients, and assessing the risk factors and prognostic indicators, we can perform hierarchical diagnosis and treatment on the high-risk population of BCBM, and achieve clinical benefits of early diagnosis and treatment. AIM To explore the clinicopathological features and prognostic factors of BCBM, and provide references for diagnosis, treatment and management of BCBM. METHODS The clinicopathological data of 68 BCBM patients admitted to the Air Force Medical Center, Chinese People’s Liberation Army (formerly Air Force General Hospital) from 2000 to 2022 were collected. Another 136 BC patients without BM were matched at a ratio of 1:2 based on the age and site of onset for retrospective analysis. Categorical data were subjected to χ 2 test or Fisher’s exact probability test, and the variables with P < 0.05 in the univariate Cox proportional hazards model were incorporated into the multivariate model to identify high-risk factors and independent prognostic factors of BCBM, with a hazard ratio (HR) > 1 suggesting poor prognostic factors. The survival time of patients was estimated by the Kaplan–Meier method, and overall survival was compared between groups by log-rank test. RESULTS Multivariate Cox regression analysis showed that patients with stage III/IV tumor at initial diagnosis [HR: 5.58, 95% confidence interval (CI): 1.99–15.68], lung metastasis (HR: 24.18, 95%CI: 6.40–91.43), human epidermal growth factor receptor 2 (HER2)-overexpressing BC and triple-negative BC were more prone to BM. As can be seen from the prognostic data, 52 of the 68 BCBM patients had died by the end of follow-up, and the median time from diagnosis of BC to the occurrence of BM and from the occurrence of BM to death or last follow-up was 33.5 and 14 mo, respectively. It was confirmed by multivariate Cox regression analysis that patients with neurological symptoms (HR: 1.923, 95%CI: 1.005–3.680), with bone metastasis (HR: 2.011, 95%CI: 1.056-3.831), and BM of HER2-overexpressing and triple-negative BC had shorter survival time. CONCLUSION HER2-overexpressing, triple-negative BC, late tumor stage and lung metastasis are risk factors of BM. The presence of neurological symptoms, bone metastasis, and molecular type are influencing prognosis factors of BCBM.


  • Peutz-Jeghers syndrome without STK11 mutation may correlate with less severe clinical manifestations in Chinese patients

    by Li-Xin Jiang, Yu-Rui Chen, Zu-Xin Xu, Yu-Hui Zhang, Zhi Zhang, Peng-Fei Yu, Zhi-Wei Dong, Hai-Rui Yang, Guo-Li Gu

    Peutz-Jeghers syndrome (PJS) is an autosomal dominant genetic disease with skin mucosal pigment spots and gastrointestinal (GI) multiple hamartoma polyps as clinical characteristics. At present, it is considered that the germline mutation of STK11 gene is the genetic cause of PJS. However, not all PJS patients can be detected STK11 germline mutations. The specific clinical characteristics of these PJS patients without STK11 mutation is an interesting clinical question. Or, like wild type GI stromal tumor, whether these PJS without STK11 mutation are also called PJS is worth discussing. Therefore, we designed the study to understand the clinical characteristics of these PJS patients without STK11 mutation. To investigates whether PJS patients with known STK11 mutations have a more severe spectrum of clinical phenotypes compared to those without. A total of 92 patients with PJS admitted to the Air Force Medical Center from 2010 to 2022 were randomly selected for study. Genomic DNA samples were extracted from peripheral blood samples, and pathogenic germline mutations of STK11 were detected by high-throughput next-generation gene sequencing. Clinical-pathologic manifestations of patients with and without STK11/LKB1 mutations were compared. STK11 germline mutations were observed in 73 patients with PJS. Among 19 patients with no detectable STK11 mutations, six had no pathogenic germline mutations of other genes, while 13 had other genetic mutations. Compared with PJS patients with STK11 mutations, those without tended to be older at the age of initial treatment, age of first intussusception and age of initial surgery. They also had a lower number of total hospitalizations relating to intussusception or intestinal obstruction, and a lower load of small intestine polyps. PJS patients without STK11 mutations might have less severe clinical-pathologic manifestations than those with.


  • Cancer Risk of Peutz–Jeghers Syndrome and Treatment Experience: A Chinese Medical Center

    by Zuxin Xu, Guoli Gu

    Peutz–Jeghers syndrome (PJS), also known as hereditary mucocutaneous pigmented gastrointestinal polyposis, is a clinically rare autosomal dominant genetic disease, which falls into the category of hereditary colorectal cancer. There are ∼7,000 new cases of PJS in China every year, and 170,000 PJS patients may survive for a long time in society. PJS polyps are characterized by an early age of onset, difficult diagnosis and treatment, and easy recurrence. With repeated growth, polyps can lead to serious complications such as intestinal obstruction, intussusception, gastrointestinal bleeding, and cancerization, which cause serious clinical problems. Due to repeated hospitalization and endoscopic follow-up, PJS patients and their families suffer from great physical and mental pain and economic burden. With the in-depth understanding of PJS and the development and popularization of endoscopic techniques in the past decade, an integrated treatment modality based on endoscopy plus surgery has gradually become the preferred treatment in most hospitals, which greatly improves the quality of life of PJS patients. However, there is still a lack of effective drug prevention and cure means. In this paper, the current clinical treatment means for PJS polyps were summarized by literature review combined with the treatment experience of our medical center, with a focus on their clinical diagnosis, treatment, and cancer risk.


  • Open Access

    Clinical features, diagnosis, and treatment of Peutz-Jeghers syndrome: Experience with 566 Chinese cases

    by Zu-Xin Xu, Li-Xin Jiang, Yu-Rui Chen, Yu-Hui Zhang, Zhi Zhang, Peng-Fei Yu, Zhi-Wei Dong, Hai-Rui Yang, Guo-Li Gu

    Clinical features, diagnosis, and treatment of Peutz-Jeghers syndrome: Experience with 566 Chinese cases